Showing 1 - 3 results of 3 for search 'Lijun Di', query time: 0.02s Refine Results
  1. 1
    Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

    Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China by Hanfang Jiang, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu, Anjie Zhu, Nan Wang, Huiping Li

    Published 2024-05-01
    Get full text
    Article
  2. 2
    Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study

    Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study by Jiaxuan Liu, Jiayang Zhang, Huiping Li, Guohong Song, Lijun Di, Hanfang Jiang, Ying Yan, Huan Wang, Jing Wang, Xiaoran Liu, Bin Shao, Qiao Li

    Published 2025-01-01
    Get full text
    Article
  3. 3
    Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer

    Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer by Bin Shao, Xiaoran Liu, Huiping Li, Guohong Song, Lijun Di, Hanfang Jiang, Ying Yan, Ruyan Zhang, Ran Ran, Jiayang Zhang, Yaxin Liu, Huan Wang, Jing Wang

    Published 2022-08-01
    Get full text
    Article

Search Tools: